1. Monash Health
  2. Monash Health research
  3. Conferences
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/40407
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZalcberg J.R.en
dc.contributor.authorStrickland A.en
dc.contributor.authorLee J.en
dc.contributor.authorCho J.Y.en
dc.contributor.authorLipton L.R.en
dc.contributor.authorSimes J.en
dc.contributor.authorPavlakis N.en
dc.contributor.authorGoldstein D.en
dc.contributor.authorYip S.en
dc.contributor.authorHarvie R.en
dc.contributor.authorMartin A.J.en
dc.contributor.authorSjoquist K.M.en
dc.contributor.authorTsobanis E.en
dc.contributor.authorKang Y.-K.en
dc.contributor.authorBang Y.-J.en
dc.contributor.authorAlcindor T.en
dc.contributor.authorO'Callaghan C.J.en
dc.contributor.authorBurnell M.J.en
dc.contributor.authorTebbutt N.C.en
dc.contributor.authorYoung Rha S.en
dc.date.accessioned2021-05-14T13:49:16Zen
dc.date.available2021-05-14T13:49:16Zen
dc.date.copyright2016en
dc.date.created20160326en
dc.date.issued2016-04-01en
dc.identifier.citationJournal of Clinical Oncology. Conference: 2016 Gastrointestinal Cancers Symposium. San Francisco, CA United States. Conference Publication: (var.pagings). 34 (4 SUPPL. 1) (no pagination), 2016. Date of Publication: 01 Feb 2016.en
dc.identifier.issn0732-183Xen
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/40407en
dc.description.abstractBackground: The INTEGRATE study evaluated activity of regorafinib (REG) v placebo (PBO) in 147 eligible patients with refractory AOGC. REG was highly effective in prolonging progression free survival (PFS). Differences between regions (i.e. Australia New Zealand/Canada (ANZ/CAN) vs Korea) were found in the magnitude of effect, but REG was effective across all regions and subgroups. We report on an exploratory analysis of VEGF biomarkers to identify predictive/prognostic markers. Method(s): Protein biomarkers IL8, VEGF-A,-B,-C-D, soluble(s)VEGFR-1,-2-3 were analysed in plasma at baseline (BL) by multiplex immunoassays (Bio-Plex,BioRad) or ELISA (Abnova). Spearman statistics were used to quantify correlations between markers. Wilcoxon Rank-Sum tests were used to compare markers across regions. The prognostic and predictive value of markers was determined using cox proportional hazards analysis of PFS. Result(s): There were moderate-to-strong correlations between BL levels of IL8 and VEGF-C (rho: = 0.68), IL8 and VEGF-D (rho: = 0.66), VEGF-A and VEGF-C (rho = 0.68), VEGF-A and sVEGFR-1 (rho = 0.54); and a modest negative correlation between VEGF-D and sVEGRF-1(rho = -0.33). The regions differed according to BL levels of: VEGF-A (higher in ANZ/CAN; p = 0.0015), VEGF-B (higher in Korea; p = 0.0003), VEGF-D (higher in Korea; p <.0001), and sVEGFR-1 (higher in ANZ/CAN; p <.0001). Adjusting for treatment group, there were statistically significant negative associations between PFS and BL IL8 (p = 0.047), VEGF-A (p = 0.037) and sVEGFR-1 (p = 0.045). There was no convincing statistical evidence that any BL plasma biomarker modified the effect of REG. The effect of region on effectiveness of REG was maintained when evaluated in conjunction with BL biomarkers individually and in combination. Conclusion(s): Highplasma IL8, VEGF-A and sVEGFR-1 may be adverse prognostic factors. A predictive VEGF blood based biomarker remains elusive. A broader biomarker study including markers beyond the VEGF axis and tissue based markers is ongoing.en
dc.languageEnglishen
dc.languageenen
dc.publisherAmerican Society of Clinical Oncologyen
dc.titleEvaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) study by the Australasian Gastrointestinal Trials Group (AGITG).en
dc.typeConference Abstracten
local.date.conferencestart2016-01-21en
dc.identifier.source72224640en
dc.identifier.institution(Yip, Harvie, Martin, Sjoquist, Tsobanis, Kang, Bang, Alcindor, O'Callaghan, Burnell, Tebbutt, Young Rha, Lee, Cho, Lipton, Strickland, Zalcberg, Simes, Goldstein, Pavlakis) Sydney Catalyst Translational Cancer Research Centre, Sydney, Australia; Bill Walsh Cancer Research Laboratories, Kolling Institute, Sydney, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; NHMRC Clinical Trials Centre, University of Sydney and Cancer Care Centre, St. George Hospital, Sydney, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Seoul National University College of Medicine, Seoul, South Korea; McGill University Health Centre, Montreal, QC, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; Saint John Regional Hospital, Saint John, NB, Canada; Austin Health, Melbourne, Australia; Yonsei Cancer Center, Yonsei University Heath System, Seoul, South Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Internal Medicine, Gangnam Severance Cancer Hospital, Yonsei University College of Medicine, Seoul, South Korea; Western Health, Melbourne, Australia; Monash Medical Centre, East Bentleigh, Australia; Peter MacCallum Cancer Centre, East Melbourne, Australia; NHMRC Clinical Trials Centre, Sydney, Australia; Prince of Wales Hospital, University of New South Wales, Cancer Survivors Centre, Sydney, Australia; Department of Medical Oncology, Royal North Shore Hospital, The University of Sydney, Sydney, Australiaen
dc.description.addressS. Yipen
dc.description.publicationstatusCONFERENCE ABSTRACTen
local.date.conferenceend2016-01-23en
dc.rights.statementCopyright 2016 Elsevier B.V., All rights reserved.en
dc.identifier.affiliationmh(Yip, Harvie, Martin, Sjoquist, Tsobanis, Kang, Bang, Alcindor, O'Callaghan, Burnell, Tebbutt, Young Rha, Lee, Cho, Lipton, Strickland, Zalcberg, Simes, Goldstein, Pavlakis) Sydney Catalyst Translational Cancer Research Centre, Sydney, Australia; Bill Walsh Cancer Research Laboratories, Kolling Institute, Sydney, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia; NHMRC Clinical Trials Centre, University of Sydney and Cancer Care Centre, St. George Hospital, Sydney, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Seoul National University College of Medicine, Seoul, South Korea; McGill University Health Centre, Montreal, QC, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; Saint John Regional Hospital, Saint John, NB, Canada; Austin Health, Melbourne, Australia; Yonsei Cancer Center, Yonsei University Heath System, Seoul, South Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Internal Medicine, Gangnam Severance Cancer Hospital, Yonsei University College of Medicine, Seoul, South Korea; Western Health, Melbourne, Australia; Monash Medical Centre, East Bentleigh, Australia; Peter MacCallum Cancer Centre, East Melbourne, Australia; NHMRC Clinical Trials Centre, Sydney, Australia; Prince of Wales Hospital, University of New South Wales, Cancer Survivors Centre, Sydney, Australia; Department of Medical Oncology, Royal North Shore Hospital, The University of Sydney, Sydney, Australia-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeConference Abstract-
Appears in Collections:Conferences
Show simple item record

Page view(s)

28
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.